{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
obeticholic acid
to a specific field?
Status:
Investigational
Source:
NCT01020799: Phase 2 Interventional Completed Major Depressive Disorder
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:bioresmethrin [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Bioresmethrin is a synthetic pyrethroid insecticide. It is the (+)-trans isomer of resmethrin which itself contains a minimum of 30% bioresmethrin. Bioresmethrin is the [1R, trans] isomer of resmethrin and has greater insecticidal activity than the racemic mixture. Bioresmethrin is a potent contact insecticide effective against a wide range of household insects, plant pests, grain pests and insects found in animal housing. It exhibits a high order of insecticidal activity, which when coupled with its excellent toxicological properties, makes it potentially one of the safest and most useful insecticides now being produced.
Status:
Investigational
Source:
NCT00652158: Phase 1 Interventional Terminated Advanced Malignancies
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
MLN8054 is a reversible, ATP competitive inhibitor of recombinant Aurora A, developed by Millennium Pharmaceuticals. MLN8054 was tested in phase I clinical trials against advanced solid tumors. Reversible somnolence probably due to off-target inhibition of alpha-1 subunit of GABA-A receptor was dose limiting and prevented achievement of plasma concentrations predicted necessary for target modulation.
Status:
Investigational
Source:
NCT01651871: Phase 2 Interventional Completed Seasonal Allergic Rhinitis
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Asapiprant, also known as S-555739, a selective Prostaglandin D2 receptor 1 antagonist, participated in phase III of clinical trials in Japan and in phase II of trials in the USA for patients with Allergic rhinitis.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01340183: Phase 1 Interventional Suspended Healthy
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02434744: Phase 2 Interventional Completed Type 2 Diabetes Mellitus
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03824535: Phase 2 Interventional Recruiting Cigarette Smoker
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
FLORILGLUTAMIC ACID F-18 is a radioactive L-glutamate derivative and a tumor-specific positron emission tomography (PET) tracer. Orphan designation (EU/3/16/1632) was granted by the European Commission to Piramal Imaging GmbH, Germany, for FLORILGLUTAMIC ACID F-18 for the diagnosis of hepatocellular carcinoma. Currently, it is in phase II trial as a PET tracer in early lung cancer in patients with lung nodules.
Status:
Investigational
Source:
NCT00992745: Phase 1 Interventional Completed Prostate Cancer
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Iofolastat I-123 is a radiolabeled iodobenzylamine derivative developed by Molecular Insight Pharmaceuticals, Inc as molecular imaging pharmaceuticals for prostate cancer. Iofolastat I123 selectively binds prostate-specific membrane antigen (PSMA), which allows imaging of PSMA-expressing prostate cancer cells. In Phase I clinical trial Iofolastat I-123 localized to lesions in bone and soft tissue that correlated with radiologic evidence of metastatic prostate cancer. Minimal uptake of one of Iofolastat I-123 as seen in the prostate gland of healthy volunteers, suggesting the possibility of visualizing disease in that organ.
Status:
Investigational
Source:
NCT01859962: Phase 2 Interventional Completed Chronic Hepatitis C
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ravidasvir (RDV, ASC16) is a second‐generation, pan‐genotypic non‐structural (NS) 5A inhibitor, which inhibits viral replication and assembly. Ravidasvir exhibits high antiviral potency with EC50 0.04–1.14 nM for HCV GT1–GT6. The pharmacokinetics results indicated that steady status achieved quickly after the first dose. Metabolism studies utilizing human clinical samples showed that Ravidasvir was very stable, with only modest (~2%) metabolite formation. Biliary excretion of Ravidasvir appears to be the primary route of elimination of the absorbed dose, while renal excretion of the intact drug appears to be negligible. In clinical trans twelve-week Ravidasvir and ritonavir-boosted Danoprevir in combination with ribavirinfor 12 weeks achieve the sustained virologic response rate of 100% in treatment-naïve non-cirrhotic Asian patients with HCV GT1 infection. Ravidasvir for treatment‐naïve, non‐cirrhotic HCV GT1 patients was safe and well tolerated. There was no death, treatment‐related serious adverse events, and discontinued cases due to adverse events.
